Atlas Venture Fund IX L.P. 13D and 13G filings for Spero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-01-25 11:28 am Unchanged |
2021-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
Atlas Venture Fund IX L.P. | 1,376,968 4.260% |
0 (Unchanged) |
Filing |
| 2021-02-02 1:02 pm Unchanged |
2020-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
Atlas Venture Fund IX L.P. | 1,376,968 5.060% |
0 (Unchanged) |
Filing |